1. Academic Validation
  2. Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells

Discovery of First-in-Class Carbonic Anhydrase/Histone Deacetylase Dual Inhibitors with Antiproliferative Activity in Cancer Cells

  • J Med Chem. 2025 Nov 13;68(21):22874-22895. doi: 10.1021/acs.jmedchem.5c01788.
Murat Bozdag 1 Nabil Mroweh 1 Alessia Raucci 2 Andrea Angeli 1 Silvia Peppicelli 3 Alessio Biagioni 3 Lido Calorini 3 Daniela Trisciuoglio 4 Rino Ragno 2 Roberta Astolfi 2 Lidia Giuliani 2 Clemens Zwergel 2 Sergio Valente 2 Elena Andreucci 3 Fabrizio Carta 1 Antonello Mai 2 5 Claudiu T Supuran 1
Affiliations

Affiliations

  • 1 Università Degli Studi di Firenze, Dipartimento Neurofarba, Sezione di Scienze Farmaceutiche E Nutraceutiche, Via Ugo Schiff 6, Sesto Fiorentino, Florence I-50019, Italy.
  • 2 Department of Drug Chemistry & Technologies, Sapienza University of Rome, P. le a Moro 5, Rome 00185, Italy.
  • 3 Department of Experimental and Clinical Biomedical Sciences "Mario Serio", University of Florence, Florence 50134, Italy.
  • 4 Institute of Molecular Biology and Pathology (IBPM), National Research Council (CNR), Rome 00185, Italy.
  • 5 Pasteur Institute, Cenci-Bolognetti Foundation, Sapienza University of Rome, Piazzale Aldo Moro 5, Rome 00185 Italy.
Abstract

This study reports in vitro evidence supporting a new class of compounds capable of independently targeting the tumor-associated human (h) Carbonic Anhydrase (CA; EC 4.2.1.1) and histone deacetylase (HDAC; EC 3.5.1.98) isoforms as first-in-class agents endowed with enhanced antiproliferative effects and safety profiles when compared to their constitutive counterparts as well as to clinically used drugs. The binding modes of both the CA- and HDAC-directed moieties were investigated through X-ray and molecular modeling experiments, respectively, thus delivering detailed Structure-Activity Relationship (SAR) knowledge.

Figures
Products